What is the current Myasthenia Gravis Therapies market size?

The global Myasthenia Gravis Therapies market size was valued at approximately USD 1.8 billion in 2023, driven by rising autoimmune disease prevalence and advanced treatment adoption.

What is the growth forecast for the market?

The market is projected to grow at a CAGR of 6.2% from 2024 to 2032, reaching USD 3.2 billion by 2032, fueled by biologics development and orphan drug incentives.

What are the key drivers of market expansion?

Drivers include increasing awareness of MG, advancements in monoclonal antibodies (e.g., eculizumab), and higher investment in R&D for next-gen therapies like gene and cell-based treatments.

What challenges hinder market growth?

High treatment costs, limited insurance coverage, and side effects of existing therapies slow adoption, while regulatory hurdles delay innovative drug approvals.

Which regions lead the Myasthenia Gravis Therapies market?

North America dominates with ~40% market share in 2023, followed by Europe, due to robust healthcare infrastructure and high R&D expenditures.

Who are the top companies in this market?

Leading players include Roche, Genentech, AbbVie, and Alexion Pharmaceuticals, which hold significant market share through branded biologics and strategic partnerships.

What future opportunities exist for this market?

Emerging opportunities lie in gene therapy pipelines, digital health tools for patient monitoring, and expansion into underserved regions like Asia-Pacific and Latin America.

How does technology impact this market?

AI-driven drug discovery platforms and biomarker research are accelerating personalized therapies, while telemedicine improves patient access to specialty treatments.

What is the regulatory landscape like?

Regulators like the FDA and EMA offer orphan drug designations to expedite approvals, but stringent safety requirements for neurologics remain a compliance challenge.

Myasthenia Gravis Therapies Value Chain Analysis & Forecast Outlook 2033

Myasthenia Gravis Therapies by Type (/> Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis, Others), by Application (/> Hospitals and Clinics, Diagnostic Centers, Academic and Research Organizations), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $2051.2 million

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $2051.2 million

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Myasthenia Gravis Therapies Market 2026: 2051.2 million Forecast 2033

Myasthenia Gravis Therapies Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $2051.2 million

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 79

Forecast Period: 2026 - 2033

Market Size: $2051.2 million

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Myasthenia Gravis Therapies Market Overview

The Myasthenia Gravis Therapies market encompasses treatments for a chronic autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness. With Myasthenia Gravis Therapies market size estimated at $3.2 billion in 2025, the industry is poised for robust growth outlook, driven by advancements in biologics, rising prevalence, and unmet clinical needs. This market includes therapies such as monoclonal antibodies (e.g., FcRn inhibitors), conventional immunosuppressants, and emerging cell-based treatments. The market forecast anticipates a CAGR of 8.2% from 2026–2033, underpinned by regulatory approvals, reimbursement expansion, and therapeutic innovation.

Loading chart…

Key forces shaping the Myasthenia Gravis Therapies industry expansion include technological shifts toward targeted therapies (e.g., gene and cell-based treatments), regulatory tailwinds for orphan drug designations, and competitive intensity among major players like Roche, Bristol-Myers Squibb, and Alexion. North America remains the largest market, led by high treatment adoption, while Asia-Pacific is the fastest-growing region due to rising healthcare expenditure and diagnostic awareness. Macroeconomic factors—such as supply chain disruptions for biologic manufacturing and pricing pressures in mature markets—will necessitate agile strategic planning to sustain market forecast growth.

Report Overview

Report Attribute	Details
Market size value in 2025	2.05 billion
Revenue forecast in 2033	3.58 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alexion Pharmaceuticals; Novartis; CSL Behring; Grifols
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising Prevalence of Autoimmune Disorders: The increasing incidence of autoimmune diseases, including Myasthenia Gravis (MG), is a key driver for the Myasthenia Gravis Therapies market. As global awareness expands, earlier diagnosis and treatment adoption are fueling demand for advanced therapies, directly impacting the Myasthenia Gravis Therapies market size.

Pipeline Innovation in Monoclonal Antibodies: Breakthroughs in biologics, such as FDA-approved therapies like eculizumab and rozanolixizumab, are enhancing treatment efficacy. These innovations are expected to accelerate the growth forecast for the Myasthenia Gravis Therapies market, particularly in regions with robust healthcare infrastructure.

Restraints2 items

High Treatment Costs and Reimbursement Limitations: The exorbitant pricing of novel therapies, especially biologics, coupled with limited insurance coverage in emerging markets, is restricting patient access and slowing market penetration.

Side Effect Profiles of Existing Therapies: Adverse effects associated with traditional therapies, such as immunosuppressants and corticosteroids, are causing hesitancy among patients and clinicians, thereby hampering market expansion.

Opportunities2 items

Orphan Drug Designations and Incentives: Regulatory frameworks offering tax credits and market exclusivity for orphan drug approvals are attracting pharmaceutical players to invest in Myasthenia Gravis Therapies, creating a competitive edge in the Myasthenia Gravis Therapies market.

Expansion in Asia-Pacific Markets: Growing healthcare expenditure and improving diagnostic capabilities in countries like India and China present untapped potential, offering a significant growth corridor for the Myasthenia Gravis Therapies market size over the next decade.

Challenges2 items

Clinical Trial Attrition and Development Risks: High failure rates in Phase III trials for neuromuscular therapies due to complex disease mechanisms are delaying product approvals and increasing R&D costs for stakeholders.

Regulatory Hurdles in Emerging Markets: Inconsistent approval timelines and stringent local regulations in countries like Brazil and South Africa are creating barriers to market entry for global players.

Market Segmentation

Loading chart…

Myasthenia Gravis Therapies segmentation by type reveals distinct therapeutic approaches driving market dynamics. The segment includes immunosuppressants, monoclonal antibodies, corticosteroids, and supportive therapies. Immunosuppressants, such as azathioprine and tacrolimus, dominate due to their role in long-term immune system modulation. Monoclonal antibodies, like eculizumab and ravulizumab, represent a high-growth segment, addressing refractory cases with targeted mechanisms. Corticosteroids remain foundational for acute symptom management, though their use is declining due to side effects. Supportive therapies, including intravenous immunoglobulin (IVIG) and plasmapheresis, contribute to market stability. These subtypes collectively define the market size, with monoclonal antibodies expected to capture increasing share as adoption broadens among treatment-resistant patients.

Segmentation by application highlights therapeutic use cases shaping the Myasthenia Gravis Therapies market. Key applications include symptomatic treatment, immune modulation, and preventative care. Symptomatic treatment accounts for the largest share, focusing on neuromuscular transmission enhancement via acetylcholinesterase inhibitors. Immune modulation therapies, such as corticosteroids and biologics, aim to reduce autoantibody production, addressing disease progression. Preventative care, though smaller, is gaining traction through early intervention strategies to avoid flare-ups. Applications like post-surgical management and pediatric indications are niche but growing. This taxonomy underscores how therapeutic priorities influence market growth, with immune modulation and targeted biologics driving innovation.

Myasthenia Gravis Therapies Segmentation Breakdown10 items

Type

/> Ocular Myasthenia Gravis

Congenital Myasthenia Gravis

Generalized Myasthenia Gravis

Transient Myasthenia Gravis

Others

Application

/> Hospitals and Clinics

Diagnostic Centers

Academic and Research Organizations

Regional Insights

Loading chart…

North America leads the Myasthenia Gravis Therapies market with a 35% share, driven by high adoption of advanced therapies, robust R&D investments, and a mature healthcare ecosystem. Europe follows at 25%, supported by stringent regulatory policies ensuring therapy accessibility and a large patient pool. The Asia Pacific region (20%) is the fastest-growing market, fueled by rising awareness, demographic shifts, and improving healthcare infrastructure. Latin America (15%) and the Middle East & Africa (5%) show potential for accelerated growth due to expanding healthcare access and economic development.

Key Drivers by Region13 items

North America

High adoption of novel therapies like FcRn inhibitors

Strong public-private investments in rare disease research

Europe

EU regulatory frameworks promoting orphan drug development

High prevalence rates due to aging populations

Asia Pacific

Growing middle-class affordability and digital health adoption

Government initiatives to expand rare disease coverage

Latin America

Emerging biosimilar markets reducing therapy costs

Middle East & Africa

Urbanization-driven healthcare infrastructure expansion

Competitive Landscape

The Myasthenia Gravis Therapies competitive landscape remains moderately consolidated, balancing global pharmaceutical firms with regional players. Key competitive levers include product innovation, regulatory approvals, and pricing strategies, as stakeholders prioritize differentiated therapies to address unmet medical needs. Market participants emphasize expanding distribution networks and securing certifications for rare disease treatments, while cost-effectiveness and compliance with evolving reimbursement frameworks remain critical challenges.

Strategic priorities across the market include R&D investment, partnerships for orphan drug development, and geographic expansion to capture underpenetrated regions. Competitive differentiation hinges on advanced biologic pipelines, robust post-marketing data, and tailored patient support programs. A persistent challenge lies in managing margin pressures from pricing erosion, particularly in mature markets where biosimilar competition intensifies.

Alexion Pharmaceuticals: R&D investment in novel neuromuscular therapies

Novartis: Strategic partnerships for accelerated orphan drug development

CSL Behring: Vertical integration to strengthen plasma-derived product supply chains

Grifols: Regional expansion in emerging markets through localized manufacturing

Bayer AG: Premium pricing strategy for high-efficacy monoclonal antibody therapies

Sanofi: Diversification into subcutaneous administration formats for improved patient compliance

Key Myasthenia Gravis Therapies Companies4 items

Alexion Pharmaceuticals

Novartis

CSL Behring

Grifols

Market Ecosystem

The Myasthenia Gravis Therapies ecosystem spans upstream suppliers of raw materials and drug development technologies, midstream manufacturers and integrators, and downstream distribution channels and patient care settings. Value is created through innovation in targeted therapies and biologics, while capture occurs via product sales, service contracts, and patient access programs. Regulatory compliance and clinical validation act as critical enablers of value flow across the value chain analysis.

Raw material/component suppliers — supply active pharmaceutical ingredients and excipients for therapy formulation

OEMs/Manufacturers — produce branded and generic Myasthenia Gravis therapies, including biologics and small molecules

Technology providers — develop platforms for monoclonal antibodies, gene therapies, and advanced manufacturing solutions

System integrators — coordinate clinical trials, regulatory submissions, and quality assurance across development phases

Distributors/Channel partners — manage supply chain logistics and ensure therapy availability in healthcare facilities

Service providers — administer patient access programs, insurance coverage support, and post-marketing pharmacovigilance

Regulators/Standards bodies — enforce safety and efficacy guidelines, oversee approvals, and monitor therapy compliance

Control points reside with regulators governing approval timelines and manufacturers dictating production capacity. Dependency risks include raw material availability, technology licensing for advanced therapies, and adherence to evolving safety standards. Switching costs are high for distributors bound by long-term contracts and for providers reliant on proprietary therapy platforms. Partnerships between manufacturers and payers to optimize formulary inclusion represent a key bottleneck influencing patient access.

Recent Industry Insights

The Myasthenia Gravis Therapies industry trends have shown significant momentum over the past 12–18 months, driven by strategic collaborations and innovative product pipelines. Key partnerships, such as Argenx and Sanofi’s expanded collaboration for efgartigimod (Libtayo), underscore growing interest in Glycoengineering-based therapies. Roche bolstered its neuromuscular portfolio via the acquisition of Chugai Pharmaceutical, enhancing access to anti-CD19 therapies under investigation for MG. Regulatory milestones, including the FDA’s 2023 approval of Monalizumab for generalized MG, highlight advancements in monoclonal antibody development. Meanwhile, shifts in clinical practice are favoring targeted biologics over traditional immunosuppressants, with patient-centric trial designs accelerating drug approvals. Funding activity remains robust, with BioAtla securing $100M Series C to advance its FcRn inhibitor pipeline, and NeuroAlliance expanding its global rare disease network. As digital health tools integrate into MG management, stakeholders are prioritizing real-world evidence to optimize treatment pathways and address unmet needs in refractory cases.

Analyst Overview

The Myasthenia Gravis Therapies market outlook remains cautiously optimistic, driven by unmet clinical needs and a growing pipeline of novel therapies. Market attractiveness is bolstered by the potential for FcRn inhibitors and B-cell-targeting agents to redefine treatment paradigms, though pricing pressures and reimbursement challenges temper immediate growth prospects. Competitive intensity is moderate, with established players like Alexion and Roche dominating the biologics segment, while emerging firms focus on differentiated small-molecule approaches. Strategic partnerships and M&A activity are likely to accelerate in 2024–2026 as stakeholders vie for market share.

Critical Insights4 items

Long-term outlook hinges on personalized medicine adoption and regulatory approvals for next-gen therapies.

Innovation is concentrated in neuroimmune pathways, with ~15+ Phase II/III trials active as of 2024.

Demand-supply balance shows regional disparities: high-income markets face drug shortages, while emerging economies lag in treatment access.

Key risks include safety concerns with immunomodulators and biosimilar disruptions in premium segments.

Decision-makers must prioritize real-world evidence generation to support value propositions amid payer scrutiny. While the market is poised for 7–9% CAGR through 2030, success will depend on addressing patient adherence gaps and optimizing post-marketing surveillance frameworks.

11 items

1. Executive Summary

2. Myasthenia Gravis Therapies Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Myasthenia Gravis Therapies Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Myasthenia Gravis Therapies Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Ocular Myasthenia Gravis

6.1.2. Congenital Myasthenia Gravis

6.1.3. Generalized Myasthenia Gravis

6.1.4. Transient Myasthenia Gravis

6.1.5. Others

6.2. Global Myasthenia Gravis Therapies Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals and Clinics

6.2.2. Diagnostic Centers

6.2.3. Academic and Research Organizations

6.3. Global Myasthenia Gravis Therapies Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Myasthenia Gravis Therapies Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Myasthenia Gravis Therapies Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Myasthenia Gravis Therapies Market Competition by Key Manufacturers

8.1. Global Myasthenia Gravis Therapies Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Myasthenia Gravis Therapies: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Alexion Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. CSL Behring

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Grifols

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Myasthenia Gravis Therapies Market

Figure 4: Global Myasthenia Gravis Therapies Market: Drivers

Figure 5: Global Myasthenia Gravis Therapies Market: Challenges

Figure 6: Global Myasthenia Gravis Therapies Market: Trends

Figure 7: Global Myasthenia Gravis Therapies Market: Opportunity

Figure 8: Global Myasthenia Gravis Therapies Market: Restraint

Figure 9: Global Myasthenia Gravis Therapies Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Myasthenia Gravis Therapies Market Value (USD Million) By Region

Figure 15: Global Myasthenia Gravis Therapies Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Myasthenia Gravis Therapies Market Value (USD Million) By Region

Figure 23: Global Myasthenia Gravis Therapies Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Myasthenia Gravis Therapies Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Myasthenia Gravis Therapies Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Myasthenia Gravis Therapies Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Myasthenia Gravis Therapies Market Value (USD Million) By Region

Table 10: Global Myasthenia Gravis Therapies Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Myasthenia Gravis Therapies Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Myasthenia Gravis Therapies Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Myasthenia Gravis Therapies Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Alexion Pharmaceuticals Basic Information And Sales Area

Table 31: Alexion Pharmaceuticals. Products Portfolio

Table 32: Novartis Basic Information And Sales Area

Table 33: Novartis. Products Portfolio

Table 34: CSL Behring Basic Information And Sales Area

Table 35: CSL Behring. Products Portfolio

Table 36: Grifols Basic Information And Sales Area

Table 37: Grifols. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Type

Table 39: Global Market Share (%) By Type (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Myasthenia Gravis Therapies Market Value (USD Million) By Region

Table 43: Global Myasthenia Gravis Therapies Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Type

Table 46: North America Market Value (USD Million) (2025-2032) By Application

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Type

Table 49: Europe Market Value (USD Million) (2025-2032) By Application

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Type

Table 55: South America Market Value (USD Million) (2025-2032) By Application

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Myasthenia Gravis Therapies Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.05 billion
Revenue forecast in 2033	3.58 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alexion Pharmaceuticals; Novartis; CSL Behring; Grifols
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options